Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geovax Labs (NQ: GOVX )

3.250 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,033,272
Open 3.250
Bid (Size) 3.750 (5)
Ask (Size) 3.780 (1)
Prev. Close 3.250
Today's Range 3.250 - 3.250
52wk Range 1.090 - 9.750
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak
A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus. 
Via Benzinga
GeoVax, SIGA Technologies Shares Soar After WHO Declares Mpox A Global Health Emergency
Shares of GeoVax Labs and SIGA Technologies are surging Wednesday amid Mpox Emergency Declaration. Here's what you need to know. 
Via Benzinga

Performance

YTD
-41.44%
-41.44%
1 Month
+15.66%
+15.66%
3 Month
+88.95%
+88.95%
6 Month
+29.48%
+29.48%
1 Year
-59.49%
-59.49%

More News

Read More
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Via NewMediaWire
Exposures COVID-19
GOVX Stock Earnings: Geovax Labs Beats EPS for Q2 2024
Via InvestorPlace
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Via NewMediaWire
Exposures COVID-19
GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst
Via InvestorPlace
GeoVax Provides First Half 2024 Business Update
Via NewMediaWire
(GOVX) - Analyzing Geovax Labs's Short Interest
Via Benzinga
Why Is GeoVax (GOVX) Stock Up 110% Today?
Via InvestorPlace
Exposures COVID-19
Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review
Via NewMediaWire
GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review
Via NewMediaWire
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Via TheNewswire.com
Exposures COVID-19
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
Why GeoVax Labs Stock Is Moving Higher Thursday
Via Benzinga
Exposures COVID-19
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
Via NewMediaWire
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
Privacy Policy  |  Terms of Use  |  MNG Corporate Site Map  |  Copyright